MOTS-c peptide: benefits, dosage, side effects and what the research shows

Most of the body’s proteins are encoded in the DNA of the cell nucleus, but mitochondria, the cell’s energy-producing structures, carry a small genome of their own. In 2015, researchers at the University of Southern California reported a short open reading frame inside the mitochondrial gene for 12S ribosomal RNA that encodes a 16-amino-acid peptide. They named it MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) ^[1].

MOTS-c is therefore a natural signalling molecule, one of a small family of “mitochondrial-derived peptides” that also includes humanin ^[5]. The MOTS-c sold online is a synthetic copy of the natural sequence, made by peptide manufacturers and labelled for research use. Our guide to what research peptides are explains what that label means in practice.

Interest in MOTS-c comes mainly from its links to metabolism, exercise and ageing. It is often discussed alongside another mitochondria-targeted peptide, SS-31, although the two are unrelated: SS-31 is a designed drug that binds a mitochondrial membrane lipid, whereas MOTS-c is a natural peptide that also circulates in the blood.

MOTS-c was not the first peptide found to be encoded in mitochondrial DNA. Humanin, identified in 2001 in a screen for factors that protected nerve cells from Alzheimer’s-related damage in the laboratory, was the first ^[16]. In 2016 the same USC group that later described MOTS-c reported six further “small humanin-like peptides” (SHLPs) encoded in the same region of the mitochondrial genome as humanin. Two of them reduced cell death and improved mitochondrial metabolism in cell studies, and circulating SHLP2, like humanin, fell with age ^[15]. MOTS-c comes from a different mitochondrial gene (12S rather than 16S ribosomal RNA), which is why it is treated as a separate member of the family.

Measurements in people suggest the picture is more complicated than “levels fall with age, so topping them up helps”. In a New Zealand study of healthy men, plasma MOTS-c was lower in older men, but MOTS-c inside skeletal muscle was about 1.5 times higher in middle-aged and older men than in young men ^[17]. In 125 Chinese adults without diabetes, plasma MOTS-c was higher, not lower, in people with metabolic syndrome, and it tracked waist size and liver fat ^[18]. The authors suggested that the body may release more MOTS-c as a response to metabolic stress. These are observational findings and cannot show cause and effect.

In the 2015 study, MOTS-c’s main target appeared to be skeletal muscle. Inside cells it inhibited the folate cycle and the linked pathway that makes purines, which led to activation of AMPK, an enzyme that acts as a cellular energy sensor and increases glucose uptake and fat use ^[1]. AMPK activation is also the property that places MOTS-c on the anti-doping list.

A 2018 study from the same group found that under metabolic stress, such as glucose restriction, MOTS-c moves from the cytoplasm into the cell nucleus in an AMPK-dependent way. There it regulated a broad set of nuclear genes, including antioxidant-response genes, and interacted with stress-responsive transcription factors such as NRF2 ^[2]. The authors presented this as evidence that the mitochondrial genome can directly regulate the nuclear genome.

More recent work has proposed other roles. A 2026 study described MOTS-c as a host defence peptide with direct antibacterial activity against E. coli and MRSA in laboratory tests and in a mouse infection model, and reported that it reprogrammed mouse immune cells ^[10]. These findings are from cell and animal experiments.

Most claims about MOTS-c peptide benefits trace back to a small number of mouse studies: protection against diet-induced weight gain and insulin resistance ^[1], better running capacity at all ages ^[3], protection against metabolic changes after removal of the ovaries in female mice ^[14], and preservation of muscle during immobilisation or cancer-related wasting ^[20][21]. The sections below take each area in turn. None of these benefits has been shown in a published human treatment trial.

People also ask whether MOTS-c gives you energy. Its proposed mechanism involves AMPK, the cell’s energy sensor, and mice treated with it ran further ^[1][3], but no study has measured energy levels, fatigue or alertness in people taking it.

The founding study reported that MOTS-c injections in mice prevented insulin resistance associated with ageing and with a high-fat diet, and prevented diet-induced obesity ^[1]. The mice in these experiments received 5 mg/kg per day by intraperitoneal injection, for periods from a few days to eight weeks.

Human genetics offers indirect support. A variant found in East Asian populations (m.1382A>C) changes the 14th amino acid of MOTS-c (K14Q). In a meta-analysis of three cohorts totalling 27,527 people, men carrying the variant had a higher prevalence of type 2 diabetes, especially if they were physically inactive. In mice, the normal peptide reduced weight and improved glucose tolerance on a high-fat diet, but the K14Q version did not ^[4]. This is an association study plus animal work, not a treatment trial.

Not every result has been positive. A 2026 study on fat-derived stem cells from people with obesity found that adding MOTS-c activated AMPK but reduced cell proliferation, increased markers of cellular ageing and inflammation, and did not improve the cells’ ability to repair damaged mouse kidneys ^[11]. Reviews of the field describe MOTS-c as a promising research target for diabetes and age-related disease, while noting that the evidence is preclinical ^[5].

MOTS-c weight loss research is limited to animals. In female mice whose ovaries were removed, a model of menopause, MOTS-c treatment prevented the expected weight gain and insulin resistance, increased brown fat activity and reduced fat build-up in white fat tissue, effects that were weakened when AMPK was blocked ^[14]. This is the main study behind searches about MOTS-c for women; there are no human data in women or men.

A 2021 study in Nature Communications reported that MOTS-c improved physical performance in young, middle-aged and old mice. Mice given daily injections ran longer on a treadmill, and late-life treatment three times a week improved physical capacity and markers of healthspan in old mice ^[3].

The same paper included the main human data on MOTS-c. In 10 sedentary healthy young men who exercised on a stationary bicycle, MOTS-c levels in muscle rose about 11.9-fold after exercise, and levels in blood rose about 1.5-fold during and after exercise before returning to baseline within four hours ^[3]. This shows that the body produces more MOTS-c during exercise; it does not show that injecting it has the same effects as exercise.

The K14Q variant has also been linked to muscle make-up. In 211 healthy Japanese adults, carriers had a higher proportion of fast-twitch muscle fibres, and the variant was more common in sprint and power athletes than in controls ^[9].

Two mouse studies have looked at muscle loss. In mice with a leg immobilised in a cast for eight days, untreated animals lost about 15% of muscle mass while those given 15 mg/kg MOTS-c daily lost about 5% ^[20]. In mice with cancer-related wasting, twice-daily MOTS-c did not prevent overall weight or fat loss but preserved quadriceps mass by about 12% compared with untreated tumour-bearing mice ^[21]. Neither has been tested in people.

No randomised trial of MOTS-c in people has published results as of September 2026. A US company, CohBar, ran a phase 1a/1b study of CB4211, which it describes as an analogue of MOTS-c, in 88 healthy volunteers and people with fatty liver disease ^[8]. In a 2021 press release the company reported that the four-week phase 1b part, in 20 people with obesity and fatty liver disease, met its safety end point with no serious adverse events, and showed reductions in liver enzymes and glucose compared with placebo ^[13]. These results were announced by the company rather than published in a journal, and CB4211 is a modified molecule, not the peptide sold online.

In 2026 a phase 2a trial of MOTS-c itself began: a randomised, placebo-controlled study in an estimated 120 adults with prediabetes and overweight or obesity, using once-daily subcutaneous injections for 12 weeks ^[7]. Until such trials report, human evidence is limited to measurements of natural MOTS-c levels in observational and exercise studies.

The registration lists the trial as recruiting, with a primary outcome of change in insulin sensitivity (the Matsuda index from a glucose tolerance test) at 12 weeks and adverse events at 16 weeks. Its estimated primary completion date is February 2027 ^[7].

There is no human answer yet. In mice, effects on glucose handling and weight gain were measured after treatment periods from a few days to eight weeks ^[1], and the muscle studies ran for eight days to a few weeks ^[20][21]. The phase 2a trial will give the first controlled human data at 12 weeks ^[7].

The same applies to MOTS-c before and after photos and personal results posted online. They are not controlled, the product used is rarely tested, and diet, training and other drugs change at the same time. They cannot show what MOTS-c itself does.

Published doses are from mice. The 2015 study used 5 mg/kg per day by intraperitoneal injection ^[1], and the 2021 exercise study used 5 or 15 mg/kg per day, including an intermittent schedule of three times a week at 15 mg/kg in older mice ^[3].

No human dose has been established. The dose in the 2026 phase 2a trial is not stated in its public registration ^[7]. Animal doses should not be converted into human doses, and PepFinder does not recommend any dose. Our peptide calculator explains reconstitution arithmetic only.

Online MOTS-c dosage charts and protocols, including per-day, per-week and “for women” versions, are not based on human trials, because there are none. Questions about vials are arithmetic rather than dosing. A 10 mg vial dissolved in 2 mL of liquid gives 5 mg per mL, and on a U-100 insulin syringe (100 units per mL) each unit then holds 0.05 mg. A 40 mg vial in 2 mL gives 20 mg per mL, or 0.2 mg per unit. A MOTS-c dosage calculator does this same sum; see bacteriostatic water for the diluent usually supplied.

All published MOTS-c research in animals used injections, mostly into the abdominal cavity ^[1][3], and the human phase 2a trial uses injection under the skin once daily ^[7]. There is no published study of MOTS-c tablets, capsules, nasal spray or pre-filled pens in people or animals that we could find.

One mouse study tested oral MOTS-c directly. Injected MOTS-c eased experimental colitis, but MOTS-c given by mouth did not produce any significant improvement; only a modified version with an added cell-penetrating sequence worked orally ^[19]. The FDA stated in 2026 that it had not identified any human exposure data for MOTS-c by any route ^[25].

There are no published human safety data for injected MOTS-c. A 2026 review of approved and unapproved peptides used in sports medicine, which included MOTS-c, concluded that rigorous human safety data for these unapproved peptides are scarce and that there is potential for serious harm ^[6]. The stem-cell findings above also show that its effects can be context-dependent ^[11].

People searching for MOTS-c side effects often ask about cancer. There is no human evidence either way. Laboratory studies point in different directions depending on the setting: MOTS-c levels were lower in blood and tumour tissue from women with ovarian cancer, and added MOTS-c slowed the growth of ovarian cancer cells in the laboratory ^[22], while in a trial of women with breast cancer, circulating MOTS-c did not change with chemotherapy, with or without metformin ^[23]. None of this tests whether taking MOTS-c raises or lowers cancer risk. The FDA has said it lacks the information needed to judge whether MOTS-c would cause harm in humans ^[25].

As with any unlicensed injectable, the identity, quantity, sterility and endotoxin content of a product depend entirely on the manufacturer. Our guide to third-party peptide testing explains what independent testing can and cannot confirm.

No study has published the half-life of injected MOTS-c in people. The nearest human data are for the body’s own MOTS-c: in the exercise study, blood levels rose during and after cycling and returned to baseline within four hours ^[3]. In a laboratory comparison, a modified MOTS-c analogue had a longer half-life than MOTS-c itself, which suggests the natural peptide is broken down relatively quickly, but no figure for MOTS-c in the body was given ^[19].

MOTS-c and NAD+ are often sold side by side, but they are different kinds of molecule. NAD+ (nicotinamide adenine dinucleotide) is not a peptide: it is a coenzyme present in every cell that carries electrons in energy metabolism and also acts as a signal for enzymes such as the sirtuins. NAD+ levels decline with age, and raising them in old or diseased animals has improved health measures, which has driven research into NAD-boosting molecules such as its precursors ^[24]. MOTS-c is a 16-amino-acid peptide that acts through AMPK and gene regulation ^[1][2].

No study has compared MOTS-c with NAD+ or tested them together, so there is no evidence that one works better or that they add to each other.

SS-31 (elamipretide) and MOTS-c are both linked to mitochondria but share nothing else. SS-31 is a designed four-amino-acid peptide that binds cardiolipin in the inner mitochondrial membrane and has been through human trials, while MOTS-c is a natural peptide encoded by mitochondrial DNA with no published human treatment trial ^[1][5]. No study has compared or combined them, so an SS-31 and MOTS-c protocol has no research basis.

Combinations of MOTS-c with retatrutide, SS-31 or NAD+ are discussed online. We found no study, in animals or people, that has tested MOTS-c with any of them. Retatrutide is itself an investigational drug that has not been approved by any regulator. Any claim about how these combinations work, or what doses to use together, is not based on published research.

MOTS-c is not an approved medicine in the US, UK, EU, Canada, Australia or New Zealand. The US Anti-Doping Agency states that it is not approved by the FDA for use in humans or in compounded medications ^[12]. Its sale as a research chemical is treated differently in each country; see our legal status pages.

MOTS-c is named on the WADA Prohibited List under S4.4.1, activators of AMP-activated protein kinase, and is prohibited at all times, in and out of competition ^[12]. USADA notes that a therapeutic use exemption is highly unlikely because it has no approved therapeutic use ^[12].

In the US, MOTS-c was nominated for use by compounding pharmacies but the nomination was withdrawn. As of April 2026 the FDA lists it among bulk substances “nominated but withdrawn” from its category of substances that may present significant safety risks, noting a potential risk of immune reactions and no human exposure data ^[25]. The FDA’s Pharmacy Compounding Advisory Committee considered MOTS-c at a meeting on 23 July 2026; the FDA has not posted an outcome or acted on it ^[26]. See our US legal status page.

Elsewhere, Health Canada named MOTS-C among unauthorised peptides seized in an April 2026 advisory and said “research use only” labelling does not make such products legal ^[27]; see the Canada page. In New Zealand, Medsafe classifies mitochondria-derived peptides as prescription medicines ^[28].

MOTS-c is supplied as a freeze-dried powder. As with other research peptides, the usual practice is to keep it cold, dry and away from light, and to refrigerate it after reconstitution. See how to store peptides and bacteriostatic water.

PepFinder does not sell MOTS-c. To compare research suppliers, see compare prices, learn how to read a COA, and see which vendors use third-party tested batches.

If you are looking for MOTS-c in the UK or Australia, you can compare MOTS-c suppliers in the UK and MOTS-c prices in Australia, but check the local law first: Australia regulates imported peptides as therapeutic goods. Our guide on how to spot a fake peptide supplier covers the warning signs.